The partnership calls for SDIX to collaborate with Banyan on the development of antibodies and immuno-solutions that include custom monoclonal and polyclonal antibody development, cell line banking and cryostorage, antibody production and purification in vivo and in vitro.
Walid Qoronfleh, executive director of life sciences at SDIX, said: “We look forward to working with Banyan Biomarkers as they continue their breakthrough work addressing the unmet clinical needs for detecting TBI.
“We believe our twenty years of experience in providing immuno-solutions; from antibody to assay development, as well as our in vitro diagnostics expertise make SDIX a valuable partner for companies like Banyan.”
Fran DiNuzzo, president and CEO of SDIX, said: “We appreciate the opportunity to collaborate on this critical biomarker project with Banyan to help save and improve the lives of patients with brain injuries, including the potential of helping the brave men and women serving in our armed forces.”
Jackson Streeter, CEO of Banyan Biomarkers, said: “We look forward to working with SDIX on the development of antibodies and immuno-solutions. This is an important step in the discovery of diagnostics and treatments for TBI and other neurological disorders.”
